



TML: CS: BSE/NSE QTR-COMP: 2022-23

17th February, 2023

BSE Limited,
P. J. Towers, Dalal Street,
Mumbai-400 001.

National Stock Exchange of India Ltd.
"Exchange Plaza",
Bandra – Kurla Complex,
Bandra – East, Mumbai- 400 051.

- Ref:** 1. Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
2. BSE Scrip Code: 530199
3. NSE Scrip Code: THEMISMED

Dear Sir/Madam,

Sub:- Receipt of No Objection from the Drug Controller General of India's Office (Central Drug Control Authority)
- Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

With reference to our earlier disclosure dated 12th July, 2018 followed by our updates dated 08th July, 2019 and 27th July, 2019, we have to now inform you that the Central Licensing Authority has conveyed its no objection to the Company for manufacturing and marketing a key product, i.e Diclofenac Injection 75mg/ml which the Company had stopped manufacturing and marketing pursuant to a directive from the State Food and Drug Administration authorities.

The Company now proposes to examine various options to commercialise the said product and also deal with the pending litigation in consultation with its Legal Advisors.

This is for your information and record.

Thanking you,

Yours Faithfully,
For **THEMIS MEDICARE LTD.**

Sangameshwar Iyer
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India
***Tel.:** 91-22-67607080 ***Fax:** 91-22-67607070/ 28746621
Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat
CIN No.: L24110GJ1969PLC001590 ***Tel/ Fax No.:** **Regd. Off.:** 0260-2431447/ 2430219
***E-mail:** themis@themismedicare.com ***Website:** www.themismedicare.com